Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Freitas

Showing results (611-620 of 639) with videos related to

Pageof 64
Sort By:
Vaccines|July 27, 2022
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against <i>Leishmania infantum</i> InfectionDaniela P Lage, Danniele L Vale, Flávia P Linhares, et al.
Pathogens (Basel, Switzerland)|December 31, 2025
Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral LeishmaniasisMarcelo M Jesus, Daniela P Lage, Breno L Pimenta, et al.
European Journal of Medicinal Chemistry|July 1, 2025
Targeting dihydroorotate dehydrogenase (DHODH) for host-directed therapy: Discovery of a novel alkyne-based scaffold inhibitor effective against SARS-CoV-2Miguel M Vaidergorn, Aline D Purificação, Pedro I P Leite, et al.
Experimental Parasitology|March 21, 2024
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis speciesIsabela A G Pereira, Camila S Freitas, Raquel S B Câmara, et al.
Cytokine|February 19, 2024
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasisCamila S Freitas, Isabela A G Pereira, Daniela P Lage, et al.
Parasitology Research|October 19, 2021
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfectionNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Medical Microbiology and Immunology|April 19, 2021
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasisRafaella R Costa, João A Oliveira-da-Silva, Thiago A R Reis, et al.
Parasitology|November 28, 2024
Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasisDaniela P Lage, Danniele L Vale, Fabiana A G Maia, et al.
Tuberculosis (Edinburgh, Scotland)|February 9, 2025
Urine-based ELISA using a recombinant chimeric protein for the diagnosis of paucibacillary and multibacillary leprosyRaquel S B Câmara, Isabela A G Pereira, Geise C Espíndola, et al.
Microbial Pathogenesis|December 9, 2021
Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteinsNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Pageof 64

Showing results (611-620 of 639) with videos related to

Sort By:
Pageof 64
Vaccines|July 27, 2022
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against <i>Leishmania infantum</i> InfectionDaniela P Lage, Danniele L Vale, Flávia P Linhares, et al.
Pathogens (Basel, Switzerland)|December 31, 2025
Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral LeishmaniasisMarcelo M Jesus, Daniela P Lage, Breno L Pimenta, et al.
European Journal of Medicinal Chemistry|July 1, 2025
Targeting dihydroorotate dehydrogenase (DHODH) for host-directed therapy: Discovery of a novel alkyne-based scaffold inhibitor effective against SARS-CoV-2Miguel M Vaidergorn, Aline D Purificação, Pedro I P Leite, et al.
Experimental Parasitology|March 21, 2024
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis speciesIsabela A G Pereira, Camila S Freitas, Raquel S B Câmara, et al.
Cytokine|February 19, 2024
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasisCamila S Freitas, Isabela A G Pereira, Daniela P Lage, et al.
Parasitology Research|October 19, 2021
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfectionNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Medical Microbiology and Immunology|April 19, 2021
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasisRafaella R Costa, João A Oliveira-da-Silva, Thiago A R Reis, et al.
Parasitology|November 28, 2024
Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasisDaniela P Lage, Danniele L Vale, Fabiana A G Maia, et al.
Tuberculosis (Edinburgh, Scotland)|February 9, 2025
Urine-based ELISA using a recombinant chimeric protein for the diagnosis of paucibacillary and multibacillary leprosyRaquel S B Câmara, Isabela A G Pereira, Geise C Espíndola, et al.
Microbial Pathogenesis|December 9, 2021
Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteinsNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Pageof 64